New MDMA Trials Moving Forward To Test Ecstasy As Treatment For PTSD


New research may have found a more efficient way of treating patients who suffer from PTSD: by using MDMA, which is ecstasy in its purest form. The assisted drug treatment could be approved by the FDA.

“The medicine allows them to look at things from a different place and reclassify them. Honestly, we don’t have to do much. Each person has an innate ability to heal. We just create the right conditions.” 

— Ann Mithoefer, psychiatric nurse

MDMA, the pure form of ecstasy, will be employed in treating . The drug is also tested for its properties when it comes to treating terminally ill patients.

[Read the full story here, at Tech Times]

The tests conducted for possible  have had positive outcomes and researchers consider the approval of MDMA as a prescription drug sometime in the near future.

However, more tests should be carried out before this. The Food and Drug Administration already approved a Phase III trial as part of the procedure.

Featured Image -- 33976

MDMA – Possible Medical Solution To PTSD

The first two studies treated patients for 12 weeks, in the form of psychotherapy sessions and MDMA sessions. The MDMA sessions lasted eight hours each, during which the . After being given the drug, the patients would sit in a relaxing environment, surrounded by chill music, flowers and candles in order to suggest a calm state of mind to balance the euphoric effects of the drug. Read the rest of this entry »

Acid Test: Multidisciplinary Association for Psychedelic Studies Pursues MDMA as Treatment for Psychological Disorders


MAPS and PSTD: Scientific MDMA research works against the stigma associated with psychedelics

Known as “ecstasy” or “molly,” MDMA may soon be an effective treatment against post-traumatic stress disorder (PTSD).acid-test

[Order Tom Shroder’s book “Acid Test: LSD, Ecstasy, and the Power to Heal” from]

The Multidisciplinary Association for Psychedelic Studies (MAPS) is attempting to legalize MDMA as a prescription for certain illnesses. In a newsletter sent to their constituents on March 16, MAPS said it had received approval from the United States Drug Enforcement Agency (DEA) on Friday, March 13 for a Schedule I license for Phil Wolfson, M.D., the principal investigator in a new MAPS study. This isn’t the only time the license has been awarded to MAPS — this is currently the seventh MDMA clinical trial with DEA approval.

Featured Image -- 33976

“MDMA reduces activity in the amygdala where fear is processed and it increases activity in the frontal cortex where people put things in association and context. So people are able to look at traumatic memories.”

“Obtaining DEA approval was the last step in the complex, arduous, and lengthy
process of getting approval for our study,” Dr. Wolfson said in the newsletter.

This was the final step before initiating experiments regarding the safety and effectiveness of MDMA-assisted psychotherapy to treat anxiety associated with life-threatening illnesses. MAPS had already received approval from the Institutional Review Board, FDA and the Research Advisory Panel of California to conduct the phase-2 study.

“They’re able to separate out that it was happening then and not now. We’re saying that MDMA itself is not the medicine. It’s MDMA-assisted psychotherapy.”

— MAPS founder Rick Doblin, in an interview with CNN

Connor McKay, president of the Students for Sensible Drug Policy chapter at Northeastern, said this type of scientific research works against the stigma associated with psychedelics. McKay will also be welcoming the founder of MAPS, Rick Doblin, and former Washington Post Editor Tom Shroder, author of “Acid Test: LSD, Ecstasy, and the Power to Heal,” to Northeastern on April 3 to discuss psychedelic research.

“I think studies like this play an important role…both medical and personal. It gives a personal story to these treatments. It gives medical legitimacy to these substances.”

— Connor McKay, president of the Students for Sensible Drug Policy chapter at Northeastern

“I think studies like this play an important role … both medical and personal. It gives a personal story to these treatments. It gives medical legitimacy to these substances,” McKay said. “I don’t think people are going to stop using MDMA recreationally. I think people will see it as abusing medicine … rather than ‘you’re just doing drugs.’ This will open the medical discussion about these substances.”

MDMA, chemically called 3,4-Methylenedioxy-methamphetamine, is typically sold as ecstasy or molly, but these can contain adulterants or other substances. In a 2006 study by Vanderbilt University, only 39 percent of tablets sold as ecstasy were pure and 46 percent had no MDMA at all. Read the rest of this entry »

LSD, Reconsidered for Therapy


An LSD molecule. Credit Ben Mills

 writes:  He heard about the drug trial from a friend in Switzerland and decided it was worth volunteering, even if it meant long, painful train journeys from his native Austria and the real possibility of a mental meltdown. He didn’t have much time, after all, and traditional medicine had done nothing to relieve his degenerative spine condition.

“The effort is both political and scientific…We want to break these substances out of the mold of the counterculture and bring them back to the lab as part of a psychedelic renaissance.”

“I’d never taken the drug before, so I was feeling — well, I think the proper word for it, in English, is dread,” said Peter, 50, an Austrian social worker, in a telephone interview; he asked that his last name be omitted to protect his identity. “There was this fear that it could all go wrong, that it could turn into a bad trip.”

On Tuesday, The Journal of Nervous and Mental Disease is posting online results from the first controlled trial of LSD in more than 40 years. The study, conducted in the office of a Swiss psychiatrist near Bern, tested the effects of the drug as a complement to talk therapy for 12 people nearing the end of life, including Peter. Read the rest of this entry »